88IV - PR Newswire Asia's news - Medical/Pharmaceuticals


Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition to Biopharma SHANGHAI , Aug. 28, 2026 /PRNewswire/ -- Asieris Pharmaceuticals today released its 2026 Semi-Annual Report, showing comprehensive progress across all business segments. With the gradual realization ... 2026-08-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering SYDNEY , Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies ... 2026-08-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation NANJING, China , Aug. 28, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance ... 2026-08-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Tigermed Announces 2026 Interim Results HANGZHOU, China , Aug. 28, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical ... 2026-08-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical development and global commercialization ... 2026-08-28T Biotechnology Medical/Pharmaceuticals
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's HONG KONG , Aug. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high ... 2026-08-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
NECA Expands Telehealth Care with New Counselling and Dietitian Support NeuroEndocrine Cancer Australia strengthens free specialist support for patients, carers, and families affected by neuroendocrine cancer. ... 2026-08-28T Health Care/Hospital Medical/Pharmaceuticals
Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion INCHEON, South Korea , Aug. 28, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today announced a rights offering to raise an expected aggregate amount of KRW 3 trillion to fund investments in ... 2026-08-28T Biotechnology Chemical Health Care/Hospital Medical/Pharmaceuticals
Kazia Therapeutics Limited Announces Proposed Public Offering SYDNEY , Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies ... 2026-08-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer Durable Complete Metabolic Response Ongoing Since November 2025 ... 2026-08-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

PR Newswire Asia's news > Medical/Pharmaceuticals